# Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

> **NCT02843074** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 53 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** elotuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **PROCEDURE:** autologous stem cell transplantation

## Key facts

- **NCT ID:** NCT02843074
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-21
- **Primary completion:** 2021-07-27
- **Final completion:** 2021-10-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843074, "Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02843074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*